Is Zepbound a semaglutide? No. Zepbound is tirzepatide, not semaglutide. Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist made by Eli Lilly. Semaglutide is a single-action GLP-1 receptor agonist sold as Ozempic, Wegovy, and Rybelsus by Novo Nordisk. The two drugs have different mechanisms, manufacturers, dosing schedules, and clinical profiles.
The Brand-to-Molecule Map
Part of the confusion comes from four major brand names across two molecules. Here is the clean mapping:
| Brand Name | Generic Molecule | Manufacturer | FDA Indication |
|---|---|---|---|
| Ozempic | Semaglutide | Novo Nordisk | Type 2 diabetes |
| Wegovy | Semaglutide | Novo Nordisk | Chronic weight management |
| Rybelsus | Semaglutide (oral) | Novo Nordisk | Type 2 diabetes |
| Mounjaro | Tirzepatide | Eli Lilly | Type 2 diabetes |
| Zepbound | Tirzepatide | Eli Lilly | Chronic weight management |
Zepbound and Mounjaro are the same molecule (tirzepatide) at the same doses, differentiated only by approved indication and pen color. Wegovy and Ozempic are similarly same-molecule (semaglutide) differentiated by indication and maximum dose. Knowing the generic name matters more than the brand for understanding how the drug works.
How GLP-1 Receptor Agonists Work (Semaglutide)
Semaglutide mimics GLP-1, a natural hormone released by the gut after eating. It binds GLP-1 receptors on pancreatic beta cells (stimulating insulin release), on alpha cells (suppressing glucagon), in the stomach (slowing gastric emptying), and in the brain (signaling satiety). The combination lowers blood glucose and reduces appetite.
Semaglutide is categorized as a “GLP-1 receptor agonist” (GLP-1 RA). It is one of several drugs in this class, alongside liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon). Within the class, semaglutide is currently the most potent single-mechanism option.
How Dual GIP/GLP-1 Receptor Agonists Work (Tirzepatide)
Tirzepatide is a “twincretin” — a single molecule that activates both the GLP-1 receptor and the GIP receptor. GIP is another incretin hormone released after eating; it has insulinotropic effects and, importantly, appears to influence adipose tissue metabolism in ways GLP-1 alone does not. Activating both receptors simultaneously produces greater glucose-lowering and weight-loss effects than activating either one alone.
Tirzepatide is in a drug class of its own at present (dual GIP/GLP-1 RA). Retatrutide, an investigational triple agonist (GLP-1, GIP, and glucagon), is in late-stage trials but not yet FDA-approved. See our broader discussion of prediabetes treatment for context.
Head-to-Head Clinical Data
The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, directly compared tirzepatide 15 mg weekly against semaglutide 2.4 mg weekly in adults with obesity (without diabetes) over 72 weeks. Tirzepatide produced approximately 20.2% mean weight loss versus approximately 13.7% for semaglutide. The difference was statistically significant and clinically meaningful.
For A1C reduction in type 2 diabetes, the SURPASS trials showed tirzepatide lowering A1C by roughly 2.0-2.5% from baseline at 15 mg weekly, compared to about 1.5-1.9% for semaglutide 1-2 mg weekly. Both drugs outperform older diabetes medications substantially.
Dosing Differences
Semaglutide and tirzepatide are not interchangeable on a mg-per-mg basis. Typical maintenance doses:
- Ozempic maximum: 2 mg weekly
- Wegovy maximum: 2.4 mg weekly
- Zepbound / Mounjaro doses: 2.5, 5, 7.5, 10, 12.5, and 15 mg weekly
Tirzepatide uses higher mg numbers but this does not mean it is “six times stronger” — the molecules bind different receptors with different affinities. What matters clinically is the approved escalation schedule and maximum: 2.4 mg for semaglutide in obesity, 15 mg for tirzepatide in obesity.
Side Effects: Similar but Not Identical
Both drugs share the GI side-effect profile characteristic of incretin therapies: nausea, vomiting, diarrhea, constipation, decreased appetite. Rates are broadly similar though some analyses suggest slightly higher rates of nausea with tirzepatide at top doses. Both carry warnings for pancreatitis, gallbladder disease, and — based on rodent studies — a boxed warning for medullary thyroid carcinoma (contraindicated if personal or family history of MTC or MEN 2).
Cardiovascular outcome data differ somewhat. Semaglutide has robust cardiovascular outcome trial data (SUSTAIN-6, SELECT) showing reduced major adverse cardiac events. Tirzepatide’s dedicated cardiovascular outcomes trial (SURPASS-CVOT) is ongoing as of 2025. The ADA currently prefers semaglutide or similar agents in patients with established cardiovascular disease pending tirzepatide CVOT results.
Why the Confusion Matters
Confusing Zepbound with semaglutide can lead to several practical problems. Patients may expect identical dose escalation when the schedules differ. Patients switching between drugs may incorrectly assume 1 mg semaglutide equals 1 mg tirzepatide. Side-effect expectations differ slightly. Insurance formulary coverage is usually drug-specific (your plan may cover Wegovy but not Zepbound, or vice versa).
For patients exploring options, see our articles on prediabetes basics and the prediabetes diet, which pair well with GLP-1 or dual-agonist therapy for metabolic improvement.
Switching Between the Two
Patients often want to switch from semaglutide to tirzepatide (or vice versa) seeking better efficacy or tolerability. Switching involves stopping the current medication and starting the new one at its initiation dose — not dose-matching. For Zepbound, that means restarting at 2.5 mg weekly regardless of your previous Wegovy dose. Your clinician will decide based on clinical goals and side-effect history.
The Bottom Line
Zepbound is not a semaglutide. Zepbound is tirzepatide, a dual GIP/GLP-1 receptor agonist from Eli Lilly. Semaglutide is a single-action GLP-1 receptor agonist from Novo Nordisk, sold as Ozempic, Wegovy, and Rybelsus. The two molecules differ in mechanism, dosing, clinical data, and side-effect nuances. Always confirm the generic name on your prescription and discuss brand selection with your clinician.
This content is for educational purposes only and is not a substitute for professional medical advice. Consult your healthcare provider before starting or switching weight-management or diabetes medications.
